Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment-Reference-Cited by-同舟云学术

Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment

Published:2017-01 Issue:1 Volume:12 Page:94-101
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Li Wenbin,Zhang Jing,Guo Lei,Chuai Shannon,Shan Ling,Ying Jianming

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

2. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

3. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH;Yi;J Thorac Oncol,2011

4. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry;Mino-Kenudson;Clin Cancer Res,2010

5. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma;Ying;Ann Oncol,2013

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering immunohistochemistry in lung cancer;Critical Reviews in Oncology/Hematology;2024-08

2. Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study;Cancer Communications;2024-07-17

3. Targeted therapeutic options in early and metastatic NSCLC-overview;Pathology and Oncology Research;2024-03-28

4. Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non–Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls;Archives of Pathology & Laboratory Medicine;2023-12-06

5. Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC;Frontiers of Medicine;2023-04-03